Literature DB >> 33052749

Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An In Silico Study.

Omar S Usmani1, Benjamin Mignot2, Irvin Kendall2, Roberta De Maria3, Daniela Cocconi3, George Georges4, Nicola Scichilone5.   

Abstract

Background: Functional respiratory imaging (FRI) is a computational fluid dynamics-based technique using three-dimensional models of <span class="Species">human lungs and formulation profiles to simulate aerosol deposition.
<span class="abstract_title">Methods:
FRI was used to evaluate lung deposition of extrafine <span class="Chemical">beclomethasone dipropionate (BDP)/formoterol fumarate (FF)/glycopyrronium bromide (GB) and extrafine BDP/FF delivered through pressurized metered dose inhalers and to compare results with reference gamma scintigraphy data. FRI combined high-resolution computed tomography scans of 20 patients with moderate-to-severe chronic obstructive pulmonary disease (mean forced expiratory volume in 1 second 42% predicted) with in silico computational flow simulations, and incorporated drug delivery parameters to calculate aerosol airway deposition. Inhalation was simulated using profiles obtained from real-life measurements.
Results: Total lung deposition (proportion deposited in intrathoracic region) was similarly high for both products, with mean ± standard deviation (SD) values of 31.0% ± 5.7% and 28.1% ± 5.2% (relative to nominal dose) for BDP/FF/GB and BDP/FF, respectively. Pairwise comparison of the deposition of BDP and FF gave a mean intrathoracic BDP/FF/GB:BDP/FF deposition ratio of 1.10 (p = 0.0405). Mean intrathoracic, central and peripheral deposition ratios for BDP were 1.09 (95% confidence interval [CI]: 1.05-1.14), 0.92 (95% CI: 0.89-0.96), and 1.20 (95% CI: 1.15-1.26), respectively, and for FF were 1.11 (95% CI: 1.07-1.15), 0.94 (95% CI: 0.91-0.98), and 1.21 (95% CI: 1.15-1.27), within the bioequivalence range (0.80-1.25) for intrathoracic and central regions, and slightly exceeding the upper boundary in the peripheral region. Mean ± SD central:peripheral deposition (C:P) was 0.48 ± 0.13 for BDP/FF/GB and 0.62 ± 0.17 for BDP/FF, indicating a higher proportion of drug deposition in the small airways than in the large airways.
Conclusion: FRI demonstrated similar deposition patterns for extrafine BDP/FF/GB and BDP/FF, with both having a high lung deposition. Moreover, the deposition patterns of BDP and FF were similar in both products. Furthermore, the C:P ratios of both products indicated a high peripheral deposition, supporting small airway targeting and delivery of these two extrafine fixed combinations, with a small difference in ratios potentially due to mass median aerodynamic diameters.

Entities:  

Keywords:  combination drug; extrafine; functional respiratory imaging; inhaled corticosteroid; lung deposition; pressurized metered-dose inhaler

Year:  2020        PMID: 33052749     DOI: 10.1089/jamp.2020.1601

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  4 in total

1.  Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study.

Authors:  Omar S Usmani; Simonetta Baldi; Simon Warren; Ilaria Panni; Luca Girardello; François Rony; Glyn Taylor; Wilfried DeBacker; George Georges
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2022-02-04       Impact factor: 3.440

2.  Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone.

Authors:  David B Price; William Henley; José Eduardo Delfini Cançado; Leonardo M Fabbri; Huib A M Kerstjens; Alberto Papi; Nicolas Roche; Elif Şen; Dave Singh; Claus F Vogelmeier; Sara Barille; Elena Nudo; Victoria Carter; Derek Skinner; Rebecca Vella; George Georges
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-02-15

3.  Differential Performance and Lung Deposition of Levofloxacin with Different Nebulisers Used in Cystic Fibrosis.

Authors:  Carsten Schwarz; Claudio Procaccianti; Laura Costa; Riccardo Brini; Richard Friend; Grazia Caivano; Hosein Sadafi; Charles Mussche; Nicolas Schwenck; Michael Hahn; Xabier Murgia; Federico Bianco
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

Review 4.  Impulse Oscillometry, Small Airways Disease, and Extra-Fine Formulations in Asthma and Chronic Obstructive Pulmonary Disease: Windows for New Opportunities.

Authors:  Alfredo Chetta; Nicola Facciolongo; Cosimo Franco; Laura Franzini; Alessio Piraino; Carmelina Rossi
Journal:  Ther Clin Risk Manag       Date:  2022-10-01       Impact factor: 2.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.